ABL1 and neoplasm: Here, we show that the BCR-ABL/SRC inhibitor dasatinib strongly interfered with these tumour-promoting responses, suggesting that the clinical efficiency of dasatinib may be due in part to cross-inhibition of TGF-β/ALK5 signalling.